Table 3.

Details of primary tumor diagnoses and prior treatments for each individual

PatientPrimary diagnosisSurgeryRadiotherapyChemotherapy
RL01Transitional cell carcinoma (bladder)1. Transurethral resection of bladder tumor1. Left neck (40 Gy) [P]Cisplatin (4 cycles) [A]
2. Cystoprostatectomy2. Lumbar spine [P]
RL02Squamous cell carcinoma (head and neck)Oropharynx (70 Gy) and neck (bilateral) (60 Gy) [R]1. Cisplatin/5-fluorouracil (2 cycles) [C]
2. Cisplatin/5-fluorouracil (3 cycles) [P]
RL03Squamous cell carcinoma (head and neck)1. Neck dissection1. Larynx (65 Gy) [R]Cisplatin*/5-fluorouracil/gefitinib (2 cycles) [N]
2. Total laryngectomy2. Trachea (20 Gy) [P]
RL04Adenoid cystic carcinoma (head and neck)Partial maxillectomy1. Maxilla (62 Gy) [A]
RL05Adenocarcinoma (lung)1. Docetaxel (4 cycles) [P]
2. Gefitinib (3 cycles) [P]
3. MVCarbo (4 cycles) [P]
RL06Sarcoma1. Partial pneumonectomyLung (20 Gy) [P]1. Doxorubicin/ifosfamide (6 cycles) [A]
2. Lung metastatectomy2. ET-743 (4 cycles) [P]
3. BIBF (6 cycles) [P]
RL07Adenocarcinoma (pancreas)
RL08Adenocarcinoma (prostate)Transurethral resection of prostate (×4)Pelvis (24 Gy) [P]1. Cyclophosphamide (6 cycles) [P]
2. Capecitabine (9 cycles) [P]
RL09Clear cell carcinoma (renal)1. Radical nephrectomyRight leg (dose unknown) [P]Cyclophosphamide (6 cycles) [P]
2. Surgical bone fixation (×2)Left leg (dose unknown [P])
RL10Squamous cell carcinoma (head and neck)Neck dissectionNeck (50 Gy) [A]Cisplatin/5-fluorouracil (4 cycles) [P]
RL11Adenocarcinoma (head and neck)1. Partial maxillectomyParanasal sinus (50 Gy) [A]
2. Lung metastatectomy
RL12Adenocarcinoma (colon)1. Defunctioning colostomyPelvis (45 Gy) [A]1. Oxaliplatin/capecitabine (4 cycles) [N]
2. Hartmann's procedure2. Irinotecan (4 cycles) [P]
3. Mitomycin/capecitabine (4 cycles) [P]
4. Capecitabine (4 cycles) [P]
RL13Melanoma (skin)Wide local excision of skin and sentinel lymph node biopsy
RL14Adenocarcinoma (pancreas)1. Palliative bypassGemcitabine (6 cycles) [P]
2. Small bowel resection
RL15Transitional cell carcinoma (bladder)1. Cystoureterectomy1. MVAC (4 cycles) [N]
2. Ureterectomy2. Gemcitabine/carboplatin (6 cycles) [P]
3. Inguinal block dissection3. MVAC (3 cycles) [P]
RL16Melanoma (ocular)Eye (dose unknown) [R]1. Gemcitabine/treosulphan (3 cycles) [P]
2. ES-285 (2 cycles) [P]
RL17Adenocarcinoma (colon)1. Oxaliplatin/5-fluorouracil (12 cycles) [P]
2. Irinotecan (6 cycles) [P]
3. ZK304709 (4 cycles) [P]
RL18Adenocarcinoma (stomach)Partial gastrectomy1. ECF (6 cycles) [P]
2. Mito/Carbo/Cape (2 cycles) [P]
RL19Adenocarcinoma (prostate)Prostate (dose unknown) [R]Cyclophosphamide (6 cycles) [P]
RL20Melanoma (skin)1. Wide local excision of skin1. Mitomycin (cycles unknown)
2. Pancreaticoduodenectomy2. Gemcitabine (cycles unknown)
3. Transurethral resection of bladder tumor (×4)
RL21Adenocarcinoma (colon)Hemicolectomy1. Oxaliplatin/5-fluorouracil (14 cycles) [P]
2. Irinotecan (cycles unknown) [P]
3. Irinotecan/cetuximab (3 cycles) [P]
RL22Melanoma (skin)Wide local excision of skin (×4)
RL23Adenocarcinoma (prostate)Thoracic spine (dose unknown)1. Docetaxel (4 cycles) [P]
Left femur (dose unknown)2. Mitoxantrone (5 cycles) [P]
Prostate (20 Gy)
Lumbar spine (8 Gy)
RL24Adenocarcinoma (prostate)Prostate (64 Gy)Cyclophosphamide (3 cycles) [P]
RL25Adenocarcinoma (prostate)1. Transurethral resection of prostateProstate (64 Gy)1. CP-751,871 (10 cycles) [P]
2. Docetaxel (8 cycles) [P]
RL26Adenocarcinoma (duodenum)1. Exploratory laparotomy
RL27Adenocarcinoma (endometrium)Pelvis (45 Gy)1. Paclitaxel (6 cycles) [P]
Vaginal vault brachytherapy (12 Gy)2. Carboplatin (6 cycles) [P]
3. Doxorubicin (3 cycles) [P]
RL28Melanoma (skin)1. Wide local excision of skinThoracolumbar spine (20 Gy)1. Temozolomide (2 cycles) [P]
2. Carboplatin/paclitaxel (2 cycles) [P]
RL29Squamous cell carcinoma (esophagus)1. Cisplatin/epirubicin (8 cycles) [P]
2. Docetaxel (4 cycles) [P]
RL30Adenocarcinoma (colon)1. Anterior resection of colon1. 5-Fluorouracil/folinic acid (7 cycles) [A]
2. Partial hepatectomy2. Oxaliplatin/capecitabine (9 cycles) [P]
RL31SarcomaAbdomen (54 Gy)Gemcitabine/docetaxel (4 cycles) [P]
Lumbar spine (25 Gy)
Chest wall (8 Gy)
RL32Melanoma (skin)1. Wide local excision of skinPelvis (20 Gy)1. Dacarbazine (2 cycles) [P]
2. Excision lymph node2. Sorafenib (2 cycles) [P]
3. Groin dissection (×3)
RL33Adenocarcinoma (colon)Sigmoid colectomy1. Oxaliplatin/capecitabine (7 cycles) [P]
2. Irinotecan (10 cycles) [P]
  • NOTE: Numbered events for surgical, radiotherapeutic, and chemotherapeutic interventions indicate separate treatment episodes. The intent of treatment is indicated by letters in square parentheses: R (radical), N (neoadjuvant), C (concomitant during radiotherapy), and A (adjuvant) relate to treatment given with curative intent; P (palliative) relates to treatment (radiotherapy or chemotherapy) given for symptomatic benefit. Note that patient RL07 had not received any prior therapy before commencing treatment with the study drug.

    Abbreviations: ECF, epirubicin, cisplatin, 5-fluorouracil; Mito/Carbo/Cape, mitomycin C, carboplatin, capecitabine; MVAC, methotrexate, vinblastine, doxorubicin, cisplatin; MVCarbo, mitomycin, vinblastine, carboplatin; *, carboplatin substituted for cisplatin after 1 cycle.